There's nothing 'odd' about the current lack of SP pressure at this stage of the business plan rollout!
The market now knows that the validation trial will run for the best part of 2025. As a consequence, many will perceive that there is no urgency to take a position. This is still an investment for the patient - for those with the skills and/or intuition to identify a marvellous long term opportunity and who don't mind parking their money in that opportunity with little immediate financial reward.
(Notwithstanding the substantial psychic rewards of supporting a potentially life-changing tech for so many and the quiet confidence that the required patience will, eventually, be very handsomely rewarded).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)